Alamoudi NM, 2018 Saudi Arabia
To evaluate the effect of L. reuteri Prodentis lozenges on caries- associated salivary bacterial counts (mutans streptococci and lactobacilli), dental plaque accumu lation, and salivary buffer capacity in preschool children (3-6y).
R, DB, PC 28 days
L. reuteri: 90 (4×108 CFU) Placebo: 88
L. reuteri significantly reduced mutans streptococci and lactobacilli, compared to placebo. However, there was no difference in plaque accumulation or buffer capacity between the groups.
Cannon M, 2013 USA
To evaluate and compare micro biological anti-caries effects of two probiotics: PerioBalance (=L. reuteri Prodentis) lozenges (Lr) and EvoraKids chewable tablets (EvK, blend of three streptococci strains), in children aged 6-12y and with moderate to high risk of caries. Both healthy and medically compro mised children were included.
R, open 28 days with Lr 30 days with EvK Evaluation 8 weeks after start of inter vention
L. reuteri (1 tabl/d): 30 (2×108 CFU) probiotic mix* (2 tabl/d): 30
* Str. uberis KJ2, Str. oralis KJ3, Str. rattus JH145 (EvoraKids, >100 million cfu)
Both probiotics suppressed the level of mutans streptococci and lactobacilli, compared to baseline. The difference bet ween the two probiotics was non-significant. (The CRT (Caries Risk Test) Bacteria Kit was applied for micro biological evaluations. It allows simultaneous determination of mutans streptococci and lactobacilli counts in saliva by means of selective agars.)
Cildir S, 2012
Turkey
To study effects on salivary mutans streptococci and lactobacilli in 4-12y old children with cleft lip/palate by use of L. reuteri Prodentis drops.
R, DB, PC, crossover 25 days per product
19 subjects in total L. reuteri: 19 (2×108 CFU) Placebo: 19
L. reuteri Prodentis drops did not reduce the salivary counts of mutans streptococci or total lactobacilli.
Keller MK, 2014
Denmark
To investigate the effect of L. reuteri Prodentis on early caries lesions in adolescents, aged 12-17 years, as measured by quantitative light induced fluorescence.
R, DB, PC
12 weeks
L. reuteri (2 tabl/d): 19
(4×108 CFU)
Placebo (2 tabl/d): 17
There were no statistically significant differences in fluores cence values and lesion area between the groups, neither at baseline, nor at the follow-up. Compared to baseline, there was a significant decrease in fluorescence at 12 weeks in the test group but not in the placebo group.